Product Description
Mechanisms of Action: CAR-T,CD20
Novel Mechanism: Yes
Modality: CAR-T
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Elicera
Company Location:
Company CEO:
Additional Commercial Interests: Uppsala University
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Lymphoma, B-Cell
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| CARMA-01 | P2 |
Recruiting |
Lymphoma, B-Cell |
2027-12-30 |
2024-05-10 |
Primary Endpoints|Start Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|